Kopran Limited share price
NSE: KOPRAN · ISIN INE082A01010
Key numbers
- Market cap
- ₹ 1,375 Cr
- Current price
- ₹ 284.53
- 52-week high / low
- ₹ 287 / 107
- Stock P/E
- 52.4
- Book value
- ₹ 109.8
- Dividend yield
- 1.05%
- ROCE
- 6.4%
- ROE
- 4.9%
- Debt to equity
- 0.29
- Sales growth (3 yrs)
- 7.2%
- Profit growth (3 yrs)
- -1.9%
- 1-year return
- 55.7%
About Kopran Limited
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 135 | 118 | 194 | 234 | 154 |
| Operating profit | 14 | 3 | 20 | 41 | 16 |
| Net profit | 7 | -10 | 9 | 19 | 7 |
| EPS (₹) | 1.54 | -2.06 | 1.93 | 3.91 | 1.39 |
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.